Palvella Therapeutics, Inc. PVLA
Set alert
146.33 USD +0.18 +0.12%
At close · Nov 2
146.33 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
141.98 Day range 150.00
71.55 52-week range 161.38
- YTD
- +39.80%
- 1 year
- +83.28%
- Open
- 145.04
- Prev close
- 146.15
- Mkt cap
- 2.11B
- Vol
- 303.46K
- Avg vol
- 214.17K
- EPS
- -4.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 141.98
- High
- 150.00
- Forward P/E
- -18.51
- Beta
- 0.00
- Short ratio
- 9.92
- Inst. own
- 105.05%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 141.47
- 200-d avg
- 126.93
- 1y target
- 228.40
3M chart
Events in this range
- Aug 4, 2026Earnings: -1.52; estimate -1.17; surprise -29.91%
- Sep 21, 2026Rating: Chardan Capital · Buy → Buy
- Oct 12, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 16, 2026Rating: William Blair · — → Outperform
- Oct 28, 2026Rating: Chardan Capital · Buy → Buy
Signals (21)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 23, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 3, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
Key statistics
- Market cap
- 2.11B
- Enterprise value
- 1.88B
- Trailing P/E
- 0.00
- Forward P/E
- -18.51
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 9.71
- EPS (TTM)
- -4.85
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -25.45M
- Total cash
- 250.58M
- Total debt
- 22.64M
- Return on equity
- -46.63%
- Shares outstanding
- 14.41M
- Short % of float
- 18.90%
- 50-day average
- 141.47
- 200-day average
- 126.93
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 228.40 +56.1% upside
Now 146.33
- Target (low)
- 205.00
- Target (mean)
- 228.40
- Target (high)
- 267.00
Ratings (0m) 16 16 buy · 0 hold · 0 sell
- Strong buy0
- Buy16
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -1.73.
Financials — quick view
PVLA Revenue — quarterly 0
PVLA Net income — quarterly -21.87M
PVLA EPS — quarterly -1.52
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -1.78 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -1.17 | -1.52 | -0.35 | -29.91% |
| May 7, 2026 | Mar 31, 2026 | -0.90 | -1.20 | -0.30 | -33.33% |
| Mar 31, 2026 | Dec 31, 2025 | -0.91117 | -1.08 | -0.17 | -18.53% |
| Nov 11, 2025 | Sep 30, 2025 | -0.85 | -1.03 | -0.18 | -21.18% |
| Aug 14, 2025 | Jun 30, 2025 | -0.78 | -0.86 | -0.08 | -10.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Chardan Capital | main | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 12, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 21, 2026 | Chardan Capital | main | Buy | Buy |
| May 21, 2026 | Stephens & Co. | reit | Overweight | Overweight |
| May 21, 2026 | Chardan Capital | main | Buy | Buy |
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- palvellatx.com
News
- Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
- Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set
- Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands
- William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating
- Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
- Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
- Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday
- HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246
- Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger
- Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations
Your note
Sign in to keep a note on PVLA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOIN KATHLEEN | Chief Operating Officer | Sale | Aug 18, 2026 | 0 |
| HERON ELAINE J | Director | Purchase | Feb 26, 2026 | 53,691 |
| JENKINS GEORGE M | Director | Sale | Oct 13, 2026 | 146,132 |
| KIRITSY CHRISTOPHER P | Director | Sale | Sep 1, 2026 | 250 |
| KORENBERG MATTHEW E | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 11, 2026 | 1,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Montanova Capital LLC | 7.88% | 1,135,406 | 166.14M | Jun 29, 2026 |
| Jennison Associates LLC | 6.67% | 960,619 | 140.57M | Jun 29, 2026 |
| Blackrock Inc. | 6.37% | 918,357 | 134.38M | Jun 29, 2026 |
| Frazier Life Sciences Management, L.P. | 6.12% | 882,400 | 129.12M | Jun 29, 2026 |
| First Light Asset Management, LLC | 5.36% | 771,901 | 112.95M | Jun 29, 2026 |
| BVF Inc. | 4.67% | 672,789 | 98.45M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.70% | 388,390 | 56.83M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.51% | 362,314 | 53.02M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.14% | 308,699 | 45.17M | Sep 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 1.92% | 276,556 | 40.47M | Jul 30, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.61% | 231,484 | 33.87M | Jun 29, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 1.46% | 209,825 | 30.70M | Jul 30, 2026 |